Sign in

NCT07471282Not yet recruitingPhase 3

Reperfusion Completion Via Local Arterial Infusion of Tenecteplase After Incomplete Mechanical Thrombectomy

Effectiveness and Safety of Intra-arterial Tenecteplase Bridging Therapy Following Incomplete Recanalization After Mechanical Thrombectomy for Acute Anterior Circulation Large Vessel Occlusion: A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Source: ClinicalTrials.gov · Last updated 13 Mar 2026

Brief summary (registry, in English)

To evaluate the efficacy and safety of intra-arterial TNK bridging therapy following incomplete recanalization (2b ≤ eTICI \< 3) after mechanical thrombectomy for acute anterior circulation large vessel occlusion.

Status (registry)
Not yet recruiting
Phase (registry)
Phase 3
Study type
Interventional
Enrollment
344 (estimated)
First submitted
10 Mar 2026
Start date
1 Mar 2026
Primary completion date
31 Dec 2028
Lead sponsor
Chuansheng Zhao
Diseases
Stroke
NCT number
NCT07471282

What you commit to

  • Study type: Interventional · Phase 3
  • Planned participants: 344
  • From 1 Mar 2026 to the primary completion date, 31 Dec 2028
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Systolic blood pressure ≥ 185 mmHg or diastolic blood pressure ≥ 110 mmHg, refractory to antihypertensive medication;

Other illness

  • DSA post-thrombectomy indicating dissection of the occluded artery, or intra-procedural flat-panel CT suggesting local hemorrhage or significant contrast extravasation;
  • Severe allergy or absolute contraindication to iodinated contrast media;
  • Pre-existing neurological or psychiatric disease that would interfere with the assessment of outcomes;
  • Any other condition deemed by the investigator to make the patient unsuitable for participation or to pose a significant risk to the patient.

Lab values

  • Blood glucose \< 50 mg/dL (2.8 mmol/L) or \> 400 mg/dL (22.2 mmol/L);
  • Platelet count \< 50 × 10⁹/L, or APTT \> 40 s, or PT \> 15 s;
  • Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency; or current use of oral anticoagulants with INR \> 1.7;
  • Severe renal failure, defined as serum creatinine \> 3.0 mg/dL (or 265.2 μmol/L) or glomerular filtration rate \[GFR\] \< 30 mL/min, or requiring hemodialysis or peritoneal dialysis;

Other

  • Contraindications to intravenous thrombolysis (excluding time-based criteria);
  • Baseline NIHSS score not obtained;
  • Patient unlikely to complete the 90-day follow-up (e.g., no fixed address, palliative care patient, etc.);
  • Suspected vasculitis or septic embolism;
  • Suspected aortic dissection;
  • Pregnancy or lactation;
  • Current participation in another clinical trial that could interfere with this study;

Who the study is looking for

  • Age ≥ 18 years;
  • Time from symptom onset or last known well to randomization within 24 hours;
  • Clinical diagnosis of acute ischemic stroke caused by acute occlusion of the intracranial anterior circulation large vessels confirmed by CTA/MRA/DSA, including occlusion of the intracranial segment of the internal carotid artery, the M1 or M2 segments of the middle cerebral artery, with or without concomitant occlusion of the ipsilateral extracranial segment of the internal carotid artery;
  • NIHSS score ≥ 6, and meeting the current guidelines for mechanical thrombectomy;
  • Anterior circulation large vessel stroke due to occlusion of the intracranial ICA, MCA M1, or M2 segments;
  • Pre-stroke mRS score ≤ 1;
  • ASPECTS score ≥ 6;
  • Post-mechanical thrombectomy status with 2b ≤ eTICI \< 3, and the operator has decided not to attempt further mechanical recanalization of the occluded vessel;
  • No more than 3 passes with the thrombectomy device;
  • Signed informed consent obtained from the patient or their legal guardian.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
The First Affiliated Hospital of China Medical University
Coordinator of this site? Confirm its status
ShenyangChinaUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.